Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

被引:236
作者
Kut, C. [1 ]
Mac Gabhann, F. [1 ]
Popel, A. S. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA
关键词
breast cancer; colorectal cancer; prostate cancer; serum; platelets; leukocytes;
D O I
10.1038/sj.bjc.6603923
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor ( VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human cancer. Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by measuring changes in VEGF concentrations in blood. In blood, the VEGF may be located in the plasma, or in the blood-borne cells and formed elements, in particular, platelets and leukocytes. In this study, we collate the measurements of VEGF in platelets, leukocytes, plasma and serum for breast, prostate, colorectal and other cancers. In addition, we analysed the concentration of VEGF in tumour tissue itself, as well as for other tissues in the human body. Although the concentration of VEGF in tumours is high, the size of tumours is small compared to other tissues, in particular, skeletal muscle. Thus, the total quantity of VEGF in tumours and in blood is small compared to the quantity in muscles. This large reservoir of VEGF may have important implications for the treatment of cancer.
引用
收藏
页码:978 / 985
页数:8
相关论文
共 105 条
[1]  
Adams J, 2000, CANCER RES, V60, P2898
[2]  
[Anonymous], 1984, GEIGY SCI TABLES
[3]  
Baker EA, 2000, J CLIN PATHOL-MOL PA, V53, P307
[4]   Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer [J].
Bando, H ;
Weich, HA ;
Brokelmann, M ;
Horiguchi, S ;
Funata, N ;
Ogawa, T ;
Toi, M .
BRITISH JOURNAL OF CANCER, 2005, 92 (03) :553-561
[5]  
Bauer KS, 1999, CLIN CANCER RES, V5, P2324
[6]   Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts [J].
Bhujwalla, ZM ;
Artemov, D ;
Natarajan, K ;
Ackerstaff, E ;
Solaiyappan, M .
NEOPLASIA, 2001, 3 (02) :143-153
[7]  
Bok RA, 2001, CANCER RES, V61, P2533
[8]   Vascular endothelial growth factor (VEGF) -: a valuable serum tumour marker in patients with colorectal cancer? [J].
Broll, R ;
Erdmann, H ;
Duchrow, M ;
Oeverman, E ;
Schwandner, O ;
Markert, U ;
Bruch, HP ;
Windhövel, U .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (01) :37-42
[9]   Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis [J].
Caine, GJ ;
Lip, GY ;
Blann, AD .
ANNALS OF MEDICINE, 2004, 36 (04) :273-277
[10]   Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1 [J].
Caine, GJ ;
Blann, AD ;
Stonelake, PS ;
Ryan, P ;
Lip, GYH .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (10) :883-890